Which is the closing point, and the uncomfortable one. Each corner is currently legislating as though the unit of regulation ...

AstraZeneca’s ETCAMAH ® (camizestrant) in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (abemaciclib, ...

Rznomics Inc. (KOSDAQ: 476830), a biopharmaceutical company specializing in the development of RNA-based gene therapies, ...

Partnership integrates Evinova’s Unified Trial Solution with Lothar Medical’s three-in-one respiratory device to streamline ...

Novonesis will expand its facility in Patalganga and build one of the world's most advanced enzyme production facilities. The ...

AtomVie Global Radiopharma (AtomVie), a leading global Contract Development and Manufacturing Organization (CDMO) in the ...

Through a memorandum of understanding, Tucker Medical and GE HealthCare intend to explore clinical education, knowledge ...

"The FDA clearance of ACE723 marks an important milestone for our AD2C platform and brings our first AD2C-generated candidate into clinical development," said Sonny Hsiao, Ph.D., Chief Executive ...

HARMONi-2 is a randomized, double-blind, multicenter, registrational Phase III trial evaluating ivonescimab, Akeso's first-in ...

AI-enabled enhancements to ISPRI™, its proprietary in silico platform for assessing the immunogenicity risk of ...

Led by the Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, a randomized, open-label, multicenter ...

The pharmaceutical services major increases its interim shareholder payout from RMB 1.03 billion in 2025, while continuing to ...